GSK-3 inhibitor (CrystalGenomics)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameGSK-3 inhibitor (CrystalGenomics)
Drug Alias NameGSK-3 inhibitors (CrystalGenomics)CG-701448CG-9CG-701446CG-701338
ClassificationSmall molecules
Mechanisms of ActionGlycogen synthase kinase-3 inhibitorsAnticancer protein kinase inhibitorsNeuroprotectants
TargetsGlycogen synthase kinase-3
Therapy Area/IndicationsSchizophreniaAlzheimer DiseaseNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCrystalgenomics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCrystalgenomics Inc
Active IndicationsN/A
Inactive IndicationsSchizophreniaAlzheimer DiseaseNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A